Latest News
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
16 September 2025 - VarmX, a Netherlands-based biotech company, announced on Tuesday that it has entered into a strategic collaboration with Australian biotechnology company CSL Limited (ASX:CSL) (USOTC:CSLLY) to advance the development of its lead a...
Made Scientific and Basilard BioTech partner on advancing ex vivo gene delivery for T cell and iPSC therapies
16 September 2025 - Made Scientific, a US-based cell therapy contract development and manufacturing organisation (CDMO), and Basilard BioTech, a Southern California biotechnology company involved in novel delivery technologies for cell and gene thera...
Avidity Biosciences closes USD690m public offering of common stock
16 September 2025 - Avidity Biosciences Inc (Nasdaq:RNA), a US biopharmaceutical company focused on providing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), announced on Monday that it has closed its previously ann...
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
16 September 2025 - Chinese pharmaceutical company Akeso Inc (HK:9926) announced on Monday that its proprietary next-generation humanised IgG4 monoclonal antibody targeting CD47, ligufalimab (AK117), has been granted Orphan Drug Designation (ODD) by ...
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
15 September 2025 - Biopharmaceutical company Forte Biosciences Inc (NASDAQ: FBRX) on Monday reported additional data from its Phase 1b trial of FB102 in celiac disease, presented at the Tampere Celiac Disease Symposium in Finland on 12 September 202...